Analysts Think There's Still Time to Get in on Edgewise, Up 332%Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineNEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.
Cytokinetics Inc. (NASDAQ: CYTK) Leading the Way in Thursday Trading Based on Percentage GainCytokinetics, Incorporated (
NASDAQ: CYTK) is one of today’s top gainers. The company’s shares have moved 1.2% on the day to $32.12.
Why Orphan Drug Designation Offers Several BenefitsPalm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we discuss the FDA’s Orphan Drug Designation program in reference to AbbVie (
NYSE: ABBV), Crispr Therapeutics AG (
NASDAQ: CRSP), Cytokinetics, Inc. (
NASDAQ: CYTK), and […]
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It includes many rare neurological disease disorders like Alzheimer’s disease, Parkinson’s disease and Multiple Sclerosis. It is also associated with aging and Traumatic brain injury. According to […]
